Gene · 4216
MAP3K4: mitogen-activated protein kinase kinase kinase 4
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. MAP3K4: mitogen-activated protein kinase kinase kinase 4. Genes, record 4216. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/4216
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q9Y6R4 | Mitogen-activated protein kinase kinase kinase 4 | 1,608 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents8
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 53977 | Q9Y6R4 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 11273 | Q9Y6R4 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 11273 | Q9Y6R4 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 52569 | Q9Y6R4 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 155540 | Q9Y6R4 | Espacenet |
| JP 2019054813 A | 2019-04-11 | 234412 | Q9Y6R4 | Espacenet |
| JP 2017121241 A | 2017-07-13 | 234412 | Q9Y6R4 | Espacenet |
| JP 2015516143 A | 2015-06-08 | 234412 | Q9Y6R4 | Espacenet |
Drugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,476
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | MAP3K4 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 12 | 2025 |
| P40OD010440 | Caenorhabditis Genetics Center | 9 | 2025 |
| P30ES006694 | Southwest Environmental Health Sciences Center | 6 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 5 | 2025 |
| P30CA016087 | Cancer Center Support Grant | 5 | 2025 |
| P30CA125123 | Baylor College of Medicine Cancer Center - Cancer Center Support Grant | 5 | 2025 |
| P42ES004940 | The DUST Center: Hazardous Dust in Drylands - Exposure, Health Impacts, and Mitigation | 5 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 4 | 2025 |
| U10CA180886 | COG NCTN Network Group Operations Center - Year 11 STAR Act MCI and PEC Supplement | 4 | 2025 |
| U10CA180899 | Children's Oncology Group Statistics and Data Center | 4 | 2025 |
1 to 10 of 1,476Source NIH's project files
See all 1,476 nih grantsPapers2,164
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
Insights from GWAS, TWAS, and DEG analysis: CDKN2B-AS1, MAP3K4, and P2RX2-encoded P2X2 receptor identified as potential therapeutic targets for ischemic heart disease in Russian adults and long-living individuals. | Front Cardiovasc Med | 2026 | 42662925 | PubTator, text mining | PubMed |
| Circular RNAs in cancer: Its biogenesis, functions, relationships with cancer progression, applications in immunotherapy and biomarker potentials. | Cancer Immunol Immunother | 2026 | 41915211 | PubTator, text mining | PubMed |
| MPK3 as a Signalling Hub in Plants: Integrating Plant Growth, Development and Stress Response. | Plants (Basel) | 2026 | 41901438 | PubTator, text mining | PubMed |
| Reactive oxygen species (ROS) in cancer: from mechanism to therapeutic implications. | Signal Transduct Target Ther | 2026 | 41881983 | PubTator, text mining | PubMed |
| ERKed by too much signaling: from oncogenic driver to therapeutic vulnerability. | Cell Mol Life Sci | 2026 | 41865130 | PubTator, text mining | PubMed |
| Crosstalk between KRAS and miRNAs in pancreatic cancer: Opportunities for its diagnosis, prognosis and therapeutic intervention (Review). | Int J Oncol | 2026 | 41860028 | PubTator, text mining | PubMed |
| Bacterial EVs contain small RNAs and transfer RNAs that regulate inflammation in lung infections. | Front Immunol | 2026 | 41789105 | PubTator, text mining | PubMed |
| Decoding organ fibrosis: mechanistic insights and emerging therapeutic strategies. | Signal Transduct Target Ther | 2026 | 41786685 | PubTator, text mining | PubMed |
| Targeting the JNK Gatekeepers: Structural Evolution and Medicinal Chemistry of MKK4 and MKK7 Inhibitors. | Molecules | 2026 | 41752451 | PubTator, text mining | PubMed |
| Let-7a and miR-34a Interplay Potent Suppressive Roles in Hepatocellular Carcinoma via Co-Targeting FNDC3B, IGF2 and SOX4. | Int J Mol Sci | 2026 | 41751849 | PubTator, text mining | PubMed |
1 to 10 of 2,164
See all 2,164 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/4216
GET https://conductscience.org/api/genes/v1/4216/grants?page=2